Literature DB >> 16861958

Evidence of graft-versus-tumor effect in refractory metastatic neuroblastoma.

Masahiro Hirayama, Eiichi Azuma, Mariko Araki, Yoshihiro Komada, Atsuko Nakagawa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16861958     DOI: 10.1097/01.tp.0000225780.90991.49

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  5 in total

1.  Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Authors:  Nicolas J Llosa; Kenneth R Cooke; Allen R Chen; Christopher J Gamper; Orly R Klein; Elias T Zambidis; Brandon Luber; Gary Rosner; Nicholas Siegel; Mary Jo Holuba; Nancy Robey; Masanori Hayashi; Richard J Jones; Ephraim Fuchs; Matthias Holdhoff; David M Loeb; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-12       Impact factor: 5.742

2.  Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.

Authors:  Kristin Baird; Terry J Fry; Seth M Steinberg; Michael R Bishop; Daniel H Fowler; Cynthia P Delbrook; Jennifer L Humphrey; Alison Rager; Kelly Richards; Alan S Wayne; Crystal L Mackall
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-05       Impact factor: 5.742

3.  Treatment of high-risk neuroblastoma.

Authors:  Ki Woong Sung
Journal:  Korean J Pediatr       Date:  2012-04-30

4.  I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma.

Authors:  Yuya Sato; Hidemitsu Kurosawa; Keitaro Fukushima; Mayuko Okuya; Susumu Hagisawa; Kenichi Sugita; Osamu Arisaka; Anri Inaki; Hiroshi Wakabayashi; Ayane Nakamura; Makoto Fukuoka; Daiki Kayano; Seigo Kinuya
Journal:  Ital J Pediatr       Date:  2012-10-15       Impact factor: 2.638

Review 5.  Recent developments in cell-based immune therapy for neuroblastoma.

Authors:  Michael R Verneris; John E Wagner
Journal:  J Neuroimmune Pharmacol       Date:  2007-03-02       Impact factor: 7.285

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.